CNBC: Novo Nordisk announces late-stage trial results for Wegovy in children aged 6 to under 12
According to CNBC, Novo Nordisk has released the full results of a late-stage trial evaluating its Wegovy injection in children aged 6 to under 12 with obesity. The analysis, which included all participating children—including those who discontinued treatment—showed that at 68 weeks, the BMI reduction in the treatment group was an average of 16.2 percentage points greater than that in the placebo group. The trial enrolled a total of 167 children, all of whom received lifestyle interventions such as diet and exercise. These are clinical trial results and should not be construed as regulatory approval for use in this age group; the impact of early intervention on the long-term disease course still requires further study.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
ASTER (Aster) dropped 23.56% in 1 hour, currently trading at $0.5225
-
2
ASTER is up 27.87% in the past hour, currently trading at $0.701
-
3
ASTER is up 17.01% in the past hour, currently trading at $0.6412
-
4
ASTER (Aster) rose 10.14% in the past 1 hour, currently trading at $0.6026
-
5
ASTER is up 20.91% in the past hour, currently trading at $0.6632
-
6
ASTER is up 13.26% in the past hour, currently trading at $0.6209
-
7
ASTER dropped 15.99% in 5 minutes, currently trading at $0.5723
-
8
ASTER surged 24.43% in the past hour, currently trading at $0.6835
-
9
ASTER (Aster) dropped 20.53% in 5 minutes, currently trading at $0.5442
-
10
TechCrunch: Indian Chip Startup Bharat Semi Secures $24 Million Seed Funding
Markets Today
Recommended Reading


